Breaking News Instant updates and real-time market news.

GBT

Global Blood Therapeutics

$56.64

-1.66 (-2.85%)

, BLUE

Bluebird Bio

$139.39

-14.75 (-9.57%)

16:55
04/17/19
04/17
16:55
04/17/19
16:55

Wedbush emerging pharmaceuticals analyst to hold a dinner

Emerging Pharmaceuticals Analyst Moussatos holds an advisor dinner with Wally Smith, MD, Sickle Cell Disease Key Opinion Leader and Professor & Scientific Director at Virginia Commonwealth University Center on Health Disparities to discuss sickle cell disease in New York on April 17 hosted by Wedbush.

GBT

Global Blood Therapeutics

$56.64

-1.66 (-2.85%)

BLUE

Bluebird Bio

$139.39

-14.75 (-9.57%)

SGMO

Sangamo

$11.70

-0.27 (-2.26%)

  • 17

    Apr

  • 06

    May

  • 09

    May

GBT Global Blood Therapeutics
$56.64

-1.66 (-2.85%)

04/01/19
WELS
04/01/19
NO CHANGE
Target $96
WELS
Outperform
Global Blood Therapeutics price target raised to $96 from $85 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Global Blood Therapeutics to $96 from $85 following senior management meetings with investors in Europe last week. Overall, the analyst came away with continued confidence in voxelotor safety and efficacy, prospects for accelerated approval, positioning within the evolving SCD market, opportunity for additional growth beyond initial labeling and broader opportunity to lead a transformation of SCD treatment in a similar way as seen previously in blood disorders like myeloma. Birchenough reiterates an Outperform rating on the shares.
02/22/19
GUGG
02/22/19
INITIATION
Target $75
GUGG
Buy
Global Blood Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated Global Blood Therapeutics with a Buy rating and $75 price target, stating that he is optimistic about the approval of voxelotor under the FDA's accelerated pathway. If approved, he thinks voxelotor could achieve about $1.45B in peak global sales, Suneja noted.
03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
BLUE Bluebird Bio
$139.39

-14.75 (-9.57%)

03/05/19
LEER
03/05/19
DOWNGRADE
LEER
Market Perform
Bluebird Bio downgraded to Market Perform from Outperform at SVB Leerink
03/05/19
03/05/19
DOWNGRADE
Target $145

Market Perform
Bluebird Bio downgraded to Market Perform on valuation at SVB Leerink
As previously reported, SVB Leerink analyst Mani Foroohar downgraded Bluebird Bio to Market Perform from Outperform, with a $145 price target. While the analyst remains optimistic on the company's ability to secure approval for BCMA, Lenti-D, and LentiGlobin programs, he believes the current valuation reflects these attractive fundamentals in line with his high probability of success assumptions.
02/25/19
RHCO
02/25/19
NO CHANGE
Target $184
RHCO
Buy
Bluebird Bio price target lowered to $184 from $223 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Bluebird Bio to $184 to reflect his updated expectations of E.U. LentiGlobin approval and bookings coming in 2020, rather 2019, along with a shallower penetration curve of the treatment in the U.S. The analyst is also keeping his Buy rating on the shares and sees Bluebird Bio as "best positioned to transition gene therapy from a scientific endeavor to a successful commercial proposition" given its "five potentially curative products in the clinic".
02/25/19
COWN
02/25/19
INITIATION
COWN
Outperform
Bluebird Bio coverage transferred with an Outperform at Cowen
Cowen analyst Yaron Werber assumed coverage on Bluebird Bio with an Outperform. The analyst believes that investors should have a strong interest in the stock, as bluebird has a deep pipeline, and is launching three drugs in 2019-2020, with "a slew of data" coming in 2019.
SGMO Sangamo
$11.70

-0.27 (-2.26%)

02/07/19
WELS
02/07/19
NO CHANGE
Target $24
WELS
Outperform
Wells Fargo says buy Sangamo on today's 'overdone' selloff
Wells Fargo analyst Jim Birchenough lowered his price target for Sangamo Therapeutics to $24 from $39 following today's update for in-vivo gene editing in mucopolysaccharidosis type I and II. While overall results are disappointing in terms of markers of sustainable efficacy and suggest further optimization required of gene editing efficiency and delivery, individual patient validation with significant iduronate-2-sulfatase enzyme production in one of two high dose MPSII patients and evidence of enzyme production in MPSI is encouraging, Birchenough tells investors in an intraday research note titled "Over Reaction To In-Vivo Gene Editing Update." The analyst believes Sangamo shares are "oversold" on today's news and recommends buying on the weakness. He maintains an Outperform rating on the name. Sangamo shares in in afternoon trading are down 36%, or $4.28, to $7.74.
02/08/19
JEFF
02/08/19
NO CHANGE
Target $23
JEFF
Buy
Jefferies sees opportunity in Sangamo after selloff, drops target to $23
Jefferies analyst Maury Raycroft says his Buy thesis on Sangamo Therapeutics is unchanged following yesterday's update. The analyst lowered his price target for the shares to $23 from $26 and maintains a Buy rating. Sangamo demonstrated successful in vivo editing, Raycroft tells investors in a research note. The analyst has confidence in the company's update, noting Sangamo was able to detect an albumin-IDS mRNA transcript in a liver biopsy aspirate that extracted around 100,000-300,000 cells for analysis. Further, concern about patient six and the transaminitis is likely an overreaction as liver enzyme elevation is consistent across gene therapy programs, adds the analyst. Raycroft sees opportunity in Sangamo shares following yesterday's selloff.
02/08/19
GSCO
02/08/19
NO CHANGE
Target $21
GSCO
Buy
Goldman says Orchard track record stands out amid disappointments in gene space
Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.
04/02/19
WELS
04/02/19
NO CHANGE
Target $34
WELS
Outperform
Sangamo price target raised to $34 from $24 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.

TODAY'S FREE FLY STORIES

IMMR

Immersion

$9.27

0.03 (0.32%)

11:45
04/25/19
04/25
11:45
04/25/19
11:45
Options
Immersion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
04/25/19
04/25
11:45
04/25/19
11:45
General news
Treasury's $85 B 4- and 8-week bill auctions were mixed »

Treasury's $85 B 4-…

11:43
04/25/19
04/25
11:43
04/25/19
11:43
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

11:43
04/25/19
04/25
11:43
04/25/19
11:43
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

FB

Facebook

$193.51

10.87 (5.95%)

, TSLA

Tesla

$251.50

-7.2 (-2.78%)

11:38
04/25/19
04/25
11:38
04/25/19
11:38
On The Fly
Facebook upgrade, Tesla downgrade among today's top calls »

Check out today's top…

FB

Facebook

$193.51

10.87 (5.95%)

TSLA

Tesla

$251.50

-7.2 (-2.78%)

PTC

PTC

$90.78

-11.16 (-10.95%)

XLNX

Xilinx

$116.64

-23.15 (-16.56%)

GD

General Dynamics

$178.46

-2.21 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 01

    May

  • 14

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

PAGS

PagSeguro Digital

$26.34

-0.14 (-0.53%)

11:35
04/25/19
04/25
11:35
04/25/19
11:35
Options
PagSeguro Digital put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

ZAYO

Zayo Group

$30.67

-1.075 (-3.39%)

11:31
04/25/19
04/25
11:31
04/25/19
11:31
Recommendations
Zayo Group analyst commentary at Wells Fargo »

Zayo weakness due to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CGI

Symbol changed to CGIP

$0.00

(0.00%)

, CGIP

Celadon Group

$0.00

(0.00%)

11:26
04/25/19
04/25
11:26
04/25/19
11:26
Hot Stocks
Celadon Group announces resolutions of DOJ, SEC investigations »

Celadon Group announced…

CGI

Symbol changed to CGIP

$0.00

(0.00%)

CGIP

Celadon Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYK

Liberty Global

$26.04

-0.35 (-1.33%)

11:25
04/25/19
04/25
11:25
04/25/19
11:25
Options
Liberty Global call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

WABC

Westamerica

$62.57

-0.87 (-1.37%)

11:21
04/25/19
04/25
11:21
04/25/19
11:21
Hot Stocks
Westamerica increases quarterly cash dividend to 41c from 40c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

11:20
04/25/19
04/25
11:20
04/25/19
11:20
General news
Energy Action: RBOB gasoline futures »

Energy Action: RBOB…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
04/25/19
04/25
11:17
04/25/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
04/25/19
04/25
11:16
04/25/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
04/25/19
04/25
11:15
04/25/19
11:15
General news
Treasury announced $75 B in 3- and 6-month bill auctions for Monday »

Treasury announced $75 B…

11:15
04/25/19
04/25
11:15
04/25/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
04/25/19
04/25
11:15
04/25/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

APC

Anadarko

$71.51

0.1 (0.14%)

11:10
04/25/19
04/25
11:10
04/25/19
11:10
Options
Bullish three-way spread in Anadarko targets an 8% move »

Bullish three-way spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 22

    May

11:09
04/25/19
04/25
11:09
04/25/19
11:09
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

11:09
04/25/19
04/25
11:09
04/25/19
11:09
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

CGI

Celadon Group

$0.00

(0.00%)

11:06
04/25/19
04/25
11:06
04/25/19
11:06
Hot Stocks
SEC charges Celadon Group with accounting fraud »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$30.27

-0.51 (-1.66%)

, DIS

Disney

$135.26

0.16 (0.12%)

11:04
04/25/19
04/25
11:04
04/25/19
11:04
Periodicals
Disney in talks to buy Comcast's 30% stake in Hulu, CNBC reports »

Disney (DIS) is in talks…

T

AT&T

$30.27

-0.51 (-1.66%)

DIS

Disney

$135.26

0.16 (0.12%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$43.75

1.88 (4.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 28

    Apr

  • 06

    May

  • 07

    May

  • 08

    May

  • 18

    May

  • 20

    May

  • 24

    Jul

11:03
04/25/19
04/25
11:03
04/25/19
11:03
General news
Kansas City Fed Manufacturing Index Level data reported »

April Kansas City Fed…

SYK

Stryker

$186.64

1.72 (0.93%)

11:02
04/25/19
04/25
11:02
04/25/19
11:02
Hot Stocks
FDA sends safety communication on use of Stryker Wingspan outside indications »

The FDA issued a safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 08

    May

  • 29

    May

CARA

Cara Therapeutics

$19.04

-0.015 (-0.08%)

11:00
04/25/19
04/25
11:00
04/25/19
11:00
Options
Call spread in Cara Therapeutics expresses a bullish view »

Call spread in Cara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$252.71

-5.99 (-2.32%)

10:59
04/25/19
04/25
10:59
04/25/19
10:59
On The Fly
Long-term bull cuts Tesla rating as profitability will not 'magically return' »

Shares of Tesla (TSLA)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.